KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Cash Flow: 2015-2025

Historic Net Cash Flow for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to $92.9 million.

  • CRISPR Therapeutics AG's Net Cash Flow rose 135.89% to $92.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year increase of 120.10%. This contributed to the annual value of -$91.3 million for FY2024, which is 151.58% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Net Cash Flow is $92.9 million, which was up 323.09% from -$41.6 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Net Cash Flow high stood at $521.8 million for Q2 2021, and its period low was -$636.3 million during Q3 2021.
  • For the 3-year period, CRISPR Therapeutics AG's Net Cash Flow averaged around $6.7 million, with its median value being $72.7 million (2024).
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 695.46% in 2021, then spiked by 3,243.38% in 2023.
  • CRISPR Therapeutics AG's Net Cash Flow (Quarterly) stood at -$88.5 million in 2021, then slumped by 223.76% to -$286.4 million in 2022, then skyrocketed by 51.61% to -$138.6 million in 2023, then surged by 152.44% to $72.7 million in 2024, then spiked by 135.89% to $92.9 million in 2025.
  • Its Net Cash Flow was $92.9 million in Q3 2025, compared to -$41.6 million in Q2 2025 and -$63.1 million in Q1 2025.